March 31, 2021

Two postdoctoral positions in Harvard Immunology: neutrophil biology, human genetics

The Nigrovic lab at Boston Children’s Hospital/Harvard Medical School seeks two new postdoctoral fellows to spearhead studies in two areas of research focus:

1) Neutrophil biology. We seek to better understand neutrophil heterogeneity and functions in inflammation, using both human and murine systems, including but not limited to the Ly6 molecule family (Blood. 2012;120:1489-98; Blood 2017 130:2092-2100; Blood Advances 2019;3:256-267; eLife 2019;8:e44031; Nature Comm 2021 in press). The applicant will have a PhD (or MD with substantial laboratory experience) related to cellular and immune biology and an interest in single-cell methodologies and/or 2-photon microscopy. Specific neutrophil experience is helpful but not required.

2) Experimental genetics to define non-coding SNPs in human autoimmune disease. We employ new experimental techniques to identify non-coding SNPs that confer risk of human disease (PLoS Genet. 2016;12:e1006292; Nature Genetics 2018;50:1180-1188). The applicant will have a PhD (or MD with substantial laboratory experience) related to genetics and/or molecular/cellular biology, potentially together with bioinformatic skills. Disease of interest include systemic lupus erythematosus, juvenile idiopathic arthritis, and rheumatoid arthritis.

The Nigrovic lab (www.nigroviclab.org) is a 13-member basic and translational research group in the Division of Immunology at Boston Children’s Hospital. We have access to abundant human samples, informative murine strains, cutting-edge single-cell methods, and a new 2-photon microscopy core. Successful applicants must be able to work independently at a high level in a friendly, collegial, and supportive but demanding environment. Potential for partial self-funding is welcome but not essential.

Inquiries and applications (including CV, name/email address of 2-3 referees to your scientific and interpersonal qualities, and reprints of 2 most significant publications) should be directed to:

Peter A. Nigrovic, MD
Chief, Division of Immunology, Boston Children’s Hospital
peter.nigrovic@childrens.harvard.edu